Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach

Krupitsky, Evgeny; Кибитов, А.О.; Blokhina, Elena; Verbitskaya, E.; Brodyansky, V. M.; Алексеева, Н. П.; Bushara, Natalia; Yaroslavtseva, T. V.; Palatkin, V.; Masalov, D.; Burakov, A.M.; Romanova, Tatyana N.; Sulimov, G Yu; Kosten, Thomas R.; Nielsen, David A.; Zvartau, Edwin; Woody, D.G.

doi:10.17116/jnevro20151154214-23

Cited by 8 publications

(4 citation statements)

References 27 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gerra et al (436) suggest that these variations in DAT1 may modulate buprenorphine-associated DA transmission and thus affect treatment success. In a study of both oral and implanted naltrexone therapy, Krupitsky et al (437) found that OUD patients with the 9-repeat VNTR allele had poor outcomes more often than successful ones on both forms of naltrexone. Thus, genotyping DAT1 VNTR could be useful in OUD therapy selection.…”

Section: The Dopamine Systemmentioning

confidence: 99%

Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders

et al. 2019

View full text Add to dashboard Cite

Opioid use in the United States has steadily risen since the 1990s, along with staggering increases in addiction and overdose fatalities. With this surge in prescription and illicit opioid abuse, it is paramount to understand the genetic risk factors and neuropsychological effects of opioid use disorder (OUD). Polymorphisms disrupting the opioid and dopamine systems have been associated with increased risk for developing substance use disorders. Molecular imaging studies have revealed how these polymorphisms impact the brain and contribute to cognitive and behavioral differences across individuals. Here, we review the current molecular imaging literature to assess how genetic variations in the opioid and dopamine systems affect function in the brain’s reward, cognition, and stress pathways, potentially resulting in vulnerabilities to OUD. Continued research of the functional consequences of genetic variants and corresponding alterations in neural mechanisms will inform prevention and treatment of OUD.

show abstract

Section: The Dopamine Systemmentioning

confidence: 99%

Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A pharmacogenetic component of the collaborative double-blind, double-dummy, placebo-controlled randomized clinical trial of implantable naltrexone vs. oral naltrexone and placebo for opioid dependence (Molecular Genetics Laboratory of the SNMRCPA, Moscow; Department of Addictions, BNMRCPN; the Laboratory of Clinical Psychopharmacology of Addictions, First Saint Petersburg Pavlov State Medical University; and Baylor College of Medicine, TX, USA) showed the joint effect of opioid receptor genes and genes of the dopaminergic system on treatment outcomes [76]. In another study, this collaborative group showed the additive effect of opioid receptor genes and dopaminergic system genes on outcomes of treatment of opioid dependence with oral naltrexone and guanfacine [77].…”

Section: The Modern Landscape Of Psychiatric Genetics In the Russian mentioning

confidence: 99%

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium

et al. 2019

View full text Add to dashboard Cite

We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.

show abstract

“…Krupitsky et al revealed that the efficacy of naltrexone treatment in patients suffering from opioid addiction was different across the patients carrying different allelic variants of the opioid receptor genes and dopaminergic system genes 44. Thus, patients carrying the combination of СС or СТ genotypes of OPRK1 and TT genotype of DRD2 demonstrated better response to treatment, whereas a combination of the A118G polymorphism of the OPRM1 gene and the VNTR polymorphism of the DAT1 gene showed a significant effect on the subjective feelings of alcohol intoxication.…”

Section: Naltrexonementioning

confidence: 99%

<p>Pharmacogenetics of alcohol addiction: current perspectives</p>

Застрожин¹,

Skryabin²,

Miroshkin³

et al. 2019

TACG

View full text Add to dashboard Cite

Genetics of alcohol addiction is currently a contradictive and complex field, where data in the most studies reflect methods’ limitations rather than meaningful and complementary results. In our review, we focus on the genetics of alcohol addiction, leaving genetics of acute alcohol intoxication out of the scope. A review of the literature on pharmacogenetic biomarkers development for the pharmacotherapy personalization reveals that today the evidence base concerning these biomarkers is still insufficient. In particular, now the researches with the design of randomized controlled trials and meta-analysis investigating the effect of the SNPs as biomarkers on the therapy efficacy are available for naltrexone only. For other medications, there are only a few studies in small samples. It decreases the possibilities to implement the pharmacogenetic algorithms for the pharmacotherapy personalization in patients with alcohol use disorders (AUD). In view of the importance of the precision approaches development not in addiction medicine only, but in other fields of medicine also to increase the efficacy and safety of the therapy, studies on pharmacogenetic biomarkers development for the medications used in patients with AUD (eg, naltrexone, disulfiram, nalmefene, acamprosate, etc.) remain relevant to this day.

show abstract

Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach

Cited by 8 publications

References 27 publications

Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders

Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium

<p>Pharmacogenetics of alcohol addiction: current perspectives</p>

Contact Info

Product

Resources

About